These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140 [TBL] [Abstract][Full Text] [Related]
9. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon. Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380 [TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. Kingma K; Wollersheim H; Thien T J Cardiovasc Pharmacol; 1995 Sep; 26(3):388-93. PubMed ID: 8583779 [TBL] [Abstract][Full Text] [Related]
11. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711 [TBL] [Abstract][Full Text] [Related]
12. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1 alpha and heparin. Ditter H; Heinrich D; Matthias FR; Sellmann-Richter R; Wagner WL; Hehrlein FW Thromb Res; 1983 Nov; 32(4):393-408. PubMed ID: 6197766 [TBL] [Abstract][Full Text] [Related]
13. Effect of vacuum curettage on the concentrations of plasma 6-keto-prostaglandin F1 alpha and serum thromboxane B2. Ylikorkala O; Mäkilä UM; Viinikka L Br J Obstet Gynaecol; 1983 Mar; 90(3):251-4. PubMed ID: 6338904 [TBL] [Abstract][Full Text] [Related]
14. [Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)]. Cabane J; Boue F; Godeau P; Lecompte T; Charpentier MC; Samama M; Nebout T Rev Med Interne; 1985 Dec; 6(5):581-9. PubMed ID: 3914023 [TBL] [Abstract][Full Text] [Related]
15. An imbalance in plasma prostanoids in patients with Raynaud's phenomenon and pulmonary vasospasm. Sakamoto K; Houya I; Inoue K; Tanaka M; Suzuki T; Sakamoto Y; Matsuo H Eur Respir J; 1999 Jan; 13(1):137-44. PubMed ID: 10836338 [TBL] [Abstract][Full Text] [Related]
16. Exercise-induced increase in plasma arachidonic acid and thromboxane B2 in healthy men: effect of beta-adrenergic blockade. Laustiola K; Seppälä E; Nikkari T; Vapaatalo H J Cardiovasc Pharmacol; 1984; 6(3):449-54. PubMed ID: 6202971 [TBL] [Abstract][Full Text] [Related]
17. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880 [TBL] [Abstract][Full Text] [Related]
18. Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels. Stampfer MJ; Jakubowski JA; Faigel D; Vaillancourt R; Deykin D Am J Clin Nutr; 1988 Apr; 47(4):700-6. PubMed ID: 3128100 [TBL] [Abstract][Full Text] [Related]
19. Prostacyclin and thromboxane A2 in thrombotic thrombocytopenic purpura. Lee SH; Wainscoat JS; Zeitlin H; Bolton FG; Leaver HA; Seawright A; Preece JM Br Med J (Clin Res Ed); 1981 Nov; 283(6303):1351-2. PubMed ID: 6797537 [TBL] [Abstract][Full Text] [Related]
20. Effects of the "vascular factor" on platelet and vascular arachidonic acid metabolism in man. Conte D; Romanelli F; Nordio M; Baldacci M; Isidori A Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):601-3. PubMed ID: 3935585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]